Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Risk of Ovarian Cancer in Patients With a Pelvic Mass

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00315692
Recruitment Status : Completed
First Posted : April 19, 2006
Last Update Posted : November 8, 2011
Sponsor:
Information provided by (Responsible Party):
Fujirebio Diagnostics, Inc.

Tracking Information
First Submitted Date April 18, 2006
First Posted Date April 19, 2006
Last Update Posted Date November 8, 2011
Study Start Date December 2005
Primary Completion Date Not Provided
Current Primary Outcome Measures
 (submitted: November 7, 2011)
Cancer vs Benign Disease
Original Primary Outcome Measures Not Provided
Change History Complete list of historical versions of study NCT00315692 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Risk of Ovarian Cancer in Patients With a Pelvic Mass
Official Title Evaluation of a Multiple Biomarker Assay to Estimate the Risk of Ovarian Cancer in Patients Presenting With a Pelvic Mass.
Brief Summary The purpose of this clinical trial is to evaluate the ability of multiple serum biomarkers to estimate the risk of ovarian cancer in women presenting with pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass).
Detailed Description

The Pelvic Mass study is a prospective, multi-center, double blind, statistically powered clinical trial that will enroll female subjects ≥18 years of age presenting to a gynecologist or gynecological oncologist with a pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass) who are scheduled to undergo surgery.

The serum tumor marker CA125 has been the most widely used marker in ovarian cancer, however, it is not sufficiently sensitive or specific for the detection of early stage disease. The levels of soluble mesothelin related peptides (SMRP) and HE4 have also recently been found to be elevated in women with ovarian cancer. The results of a pilot study suggest that the use of HE4 may improve the sensitivity of CA125 and provide for stratification of patients presenting with a pelvic mass into high, intermediate and low risk groups.

HE4 and CA125 serum levels will be evaluated in this study for their ability to stratify patients presenting with a pelvic mass into risk groups with low, intermediate or high probabilities of harboring an ovarian cancer at the time of initial presentation. The algorithm using these two serum markers to stratify patients that was developed using pilot study data will be evaluated in this prospective multicenter pelvic mass study. We will also evaluate the inclusion of additional biomarkers and risk factors, such as ultrasound score, age, and menopausal status, into the algorithm to see if there is any improvement in the stratification of patients into the risk groups.

The primary objective of the study is to estimate the risk of finding ovarian cancer at the time of surgery in pre- and post-menopausal women presenting with pelvic mass. Multiple serum biomarkers (CA125 and HE4) will be evaluated to estimate the risk that the patient is harboring an ovarian cancer at the time of presentation.

The secondary objective of the study is to develop a multivariate predictive algorithm combining CA125 and HE4 with radiological imaging results, and patient risk factors (such as age, menopausal status and ethnicity) to estimate the risk of ovarian cancer, including low malignant potential (LMP) / borderline tumors, at the time of surgery in patients presenting with a pelvic mass.

The exploratory endpoints will include the evaluation of serum, plasma and/or urine levels of CA125, HE4 and other additional novel biomarkers such as SMRP, alone and in combination with radiological imaging results and subject risk factors to determine their ability to estimate the risk of cancer at the time of surgery in patients presenting with a pelvic mass.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
Serum, plasma and urine
Sampling Method Probability Sample
Study Population Women undergoing surgery for the removal of a pelvic mass.
Condition Ovarian Cancer
Intervention Device: Biomarker Assay (CA125 and HE4)
Study Groups/Cohorts
  • Premenopausal women
    Intervention: Device: Biomarker Assay (CA125 and HE4)
  • Postmenopausal women
    Intervention: Device: Biomarker Assay (CA125 and HE4)
Publications * Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009 Jan;112(1):40-6. doi: 10.1016/j.ygyno.2008.08.031. Epub 2008 Oct 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: November 7, 2011)
566
Original Enrollment
 (submitted: April 18, 2006)
500
Actual Study Completion Date February 2007
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  • Females selected to undergo laparotomy or laparoscopy based on a finding of pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass);
  • Pre- and post-menopausal women greater than or equal to 18 years of age;
  • Pelvic mass must be demonstrated by ultrasound
  • Able to understand and sign Informed Consent

Exclusion Criteria:

  • Treatment for any malignancy (with the exception of non-melanoma skin cancer) within the last five years
  • Subjects receiving cytotoxic chemotherapies, such as cyclophosphamide or methotrexate
  • Subjects with previous bilateral oophorectomy
  • Any subject known to be pregnant
Sex/Gender
Sexes Eligible for Study: Female
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT00315692
Other Study ID Numbers FDI-03 Pelvic Mass Study
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Fujirebio Diagnostics, Inc.
Study Sponsor Fujirebio Diagnostics, Inc.
Collaborators Not Provided
Investigators
Principal Investigator: Richard Moore, M.D. Womens and Infant's Hosapital of Rhode Island
PRS Account Fujirebio Diagnostics, Inc.
Verification Date November 2011